Method of preventing and / or treating tissue damage or injury

A PAI-1 activity modifier composition addresses the lack of effective treatments for caustic esophageal and stomach strictures by reducing inflammation and promoting tissue rejuvenation, providing a non-invasive therapeutic approach.

WO2026136207A2PCT designated stage Publication Date: 2026-06-25MOREHOUSE SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
MOREHOUSE SCHOOL OF MEDICINE
Filing Date
2025-12-15
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

Current medical treatments for caustic esophageal strictures and gastrointestinal injuries, such as those caused by caustic substance ingestion, are ineffective, leading to debilitating conditions like esophageal strictures and stomach strictures, with no FDA-approved therapies available, and existing therapies like esophagectomy come with significant risks.

Method used

Administering a pharmaceutical composition comprising a plasminogen activator inhibitor-1 (PAI-1) activity modifier to reduce gastrointestinal inflammation, scar formation, and promote tissue rejuvenation and stricture prevention.

Benefits of technology

The PAI-1 activity modifier effectively reduces inflammation, scar formation, and prevents or treats esophageal and stomach strictures, offering a potential therapeutic option for caustic injuries without the need for invasive surgeries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025059598_25062026_PF_FP_ABST
    Figure US2025059598_25062026_PF_FP_ABST
Patent Text Reader

Abstract

A method of preventing and / or treating gastrointestinal damage in a subject comprising: administering in a therapeutically effective amount a pharmaceutical composition comprising a PAI-1 inhibitor to a subject having gastrointestinal damage. A method of preventing and / or treating caustic esophageal strictures in a subject comprising: administering in a therapeutically effective amount a pharmaceutical composition comprising a PAI-1 inhibitor to a subject having caustic gastrointestinal damage.
Need to check novelty before this filing date? Find Prior Art